InvestSMART

Avecho Biotechnology Limited (ASX:AVE)

ALERT: Price-sensitive ASX Announcement for AVE
Current share price for AVE : $0.022 0.007 (46.67%)+
Announcement
Release
24 Jun 2026 8:50AM
Price at Release
$0.015
Full Release
download
Summary
Avecho Biotechnology Limited announced that the independent Data Monitoring Board (DMB) has recommended continuing its Phase III clinical trial for its TPM®-enhanced CBD capsule for insomnia without increasing the number of participants. The trial, involving 244 participants so far, showed no serious adverse events. This positive interim analysis significantly de-risks the clinical development, enhances regulatory and commercial prospects, and supports ongoing licensing discussions outside Australia. The study aims to enroll a total of 519 participants and is designed to meet the requirements of major global regulatory bodies.
Key Points
  • Independent DMB recommends continuing Avecho's Phase III insomnia trial.
  • Successfully met pre-specified criteria at interim analysis.
  • Trial continues with 519 participants as planned, no increase needed.
  • No serious adverse events in 244 participants with CBD or placebo.
  • Positive outcomes de-risk Avecho's CBD TPM® product.
  • Supports regulatory and commercial development, strengthening licensing discussions.
  • The trial is a multi-centre, randomized, double-blind, placebo-controlled study.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.